SCHEMBL1102755

SCHEMBL1102755

c1ccc(-c2cc(-c3c4ccccc4c(-c4cc(-c5ccccc5)nc(-c5ccccc5)n4)c4cnccc34)nc(-c3ccccc3)n2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.47
KMT2A Q03164 7/20 0.47
ALDH1A1 P00352 5/20 0.47
HPGD P15428 4/20 0.47
MAPT P10636 3/20 0.47
NTSR1 P30989 1/20 0.47
ADORA1 P30542 4/20 0.45
ADORA2A P29274 3/20 0.45
CYP19A1 P11511 1/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C9 P11712 2/20 0.42
MAPK10 P53779 1/20 0.42
KDM4E B2RXH2 2/20 0.42
LMNA P02545 2/20 0.42
GLA P06280 2/20 0.42
TNF P01375 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MAPK1 P28482 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1102543 0.94 LATS1 (0.43) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL23996431 0.89 MEN1 (0.51) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL13649230 0.87 MEN1 (0.60) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL18623355 0.84 MEN1 (0.51) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL1102522 0.84 CYP19A1 (0.53) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL18623337 0.84 CYP3A4 (0.50) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL21778649 0.84 CYP3A4 (0.50) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL972451 0.83 MEN1 (0.56) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL18623368 0.82 MEN1 (0.59) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL18623326 0.81 MEN1 (0.54) MEN1KMT2AALDH1A1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 MEN1 4462/4885KMT2A 3930/4885ALDH1A1 1015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.